These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10725968)

  • 1. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 2. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
    Ventura GJ
    J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
    [No Abstract]   [Full Text] [Related]  

  • 5. [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
    Miyauchi M; Yamamoto N; Nakajima N; Suzuki M; Takahashi M; Ohno K; Ogawa K; Tsukamoto T; Yamamoto K; Oheda Y;
    Gan To Kagaku Ryoho; 2001 Jan; 28(1):43-8. PubMed ID: 11201379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American symposium looks at new antineoplastic drug.
    Korcok M
    Can Med Assoc J; 1985 Jul; 133(1):66-7. PubMed ID: 3891062
    [No Abstract]   [Full Text] [Related]  

  • 7. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Tanner J; Dunst J
    Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
    [No Abstract]   [Full Text] [Related]  

  • 8. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis].
    Wu WJ; Zeng J; Pan CE
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1812-4. PubMed ID: 17259127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of epirubicin in the treatment of breast neoplasm].
    Jiang ZF; Song SC
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):193-5. PubMed ID: 15949413
    [No Abstract]   [Full Text] [Related]  

  • 14. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of pharmorubicin in cancer of the breast].
    Ass NIa; Borisov VI
    Sov Med; 1986; (10):36-9. PubMed ID: 3544240
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
    Alliot C
    J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.